<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18221" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Benztropine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahuja</surname>
            <given-names>Abhimanyu</given-names>
          </name>
          <aff>Florida Atlantic University Charles E. Schmidt College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abhimanyu Ahuja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18221.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Benztropine is classified as a synthetic muscarinic receptor antagonist, also known as an anticholinergic drug, and shares a structural resemblance with diphenhydramine and atropine.&#x000a0;Benztropine is approved by the US Food and Drug Administration (FDA) as an adjunctive therapy for various forms of parkinsonism, including idiopathic and postencephalitic parkinsonism.&#x000a0;This medication extends its therapeutic application beyond Parkinson disease, effectively addressing drug-induced extrapyramidal symptoms and playing a crucial role in preventing and treating acute dystonic reactions.&#x000a0;Due to its prolonged duration of action, benztropine requires less frequent dosing than diphenhydramine.</p>
        <p>Benztropine exerts its action in the central nervous system (CNS) and smooth muscles by competing with acetylcholine at muscarinic receptors. Consequently, it reduces central cholinergic effects by blocking muscarinic receptors, which appears to alleviate the symptoms of Parkinson disease.&#x000a0;With a lower level of&#x000a0;CNS stimulation than trihexyphenidyl, benztropine is the preferred drug for geriatric patients. This activity reviews the indications, mechanism of action, administration, contraindications, and adverse effects of benztropine in managing Parkinson disease. This activity&#x000a0;is tailored to provide interprofessional healthcare team members with the knowledge necessary for making well-informed decisions regarding the use of benztropine in diverse clinical scenarios.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the approved indications for benztropine, recognizing its role as an adjunctive therapy in various forms of parkinsonism, including idiopathic and postencephalitic parkinsonism.</p></list-item><list-item><p>Implement proper dosing strategies for benztropine, considering its prolonged duration of action and adjusting dosages according to individual patient needs.</p></list-item><list-item><p>Assess patients for potential adverse effects and drug interactions associated with benztropine, emphasizing a comprehensive understanding of its impact on the central nervous system.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams to enhance patient outcomes through coordinated efforts in managing Parkinson disease and associated conditions with benztropine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18221&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18221">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18221.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Benztropine is a type of synthetic drug that falls under the category of muscarinic receptor antagonists, which are also known as anticholinergic drugs. Thus,&#x000a0;the drug shares a structural resemblance with diphenhydramine and atropine.&#x000a0;Benztropine is approved by the US Food and Drug Administration (FDA) as an adjunctive therapy for various forms of parkinsonism, including idiopathic and postencephalitic parkinsonism.&#x000a0;This medication extends its therapeutic application beyond Parkinson disease, effectively addressing drug-induced extrapyramidal symptoms and playing a crucial role in preventing and treating acute dystonic reactions.</p>
        <p>Due to its prolonged duration of action, benztropine requires less frequent dosing than diphenhydramine. Benztropine exerts its action in the central nervous system (CNS) and smooth muscles by competing with acetylcholine at muscarinic receptors. Consequently, it reduces central cholinergic effects by blocking muscarinic receptors, which appears to alleviate the symptoms of Parkinson disease.&#x000a0;With a lower level of&#x000a0;CNS stimulation than trihexyphenidyl, benztropine is the preferred drug for geriatric patients.<xref ref-type="bibr" rid="article-18221.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Benztropine is FDA-approved as an adjunctive therapy for all forms of parkinsonism, including&#x000a0;idiopathic&#x000a0;and postencephalitic parkinsonism.<xref ref-type="bibr" rid="article-18221.r2">[2]</xref><xref ref-type="bibr" rid="article-18221.r3">[3]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Benztropine is valuable in addressing drug-induced extrapyramidal symptoms, preventing dystonic reactions, and providing acute treatment for dystonic reactions.<xref ref-type="bibr" rid="article-18221.r4">[4]</xref>&#x000a0;The guidelines of the American Psychiatric Association (APA) support the use of anticholinergic medications, including benztropine, in the treatment of acute dystonia associated with antipsychotic therapy.<xref ref-type="bibr" rid="article-18221.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Benztropine is used off-label for the treatment of chronic sialorrhea in developmentally disabled patients.<xref ref-type="bibr" rid="article-18221.r6">[6]</xref>&#x000a0;The medication demonstrated a substantial response in a small study, with 85% of patients showing improvement compared to only 15% in the placebo group.<xref ref-type="bibr" rid="article-18221.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Numerous clinical studies have been conducted on the use of benztropine in the management of intractable hiccups.<xref ref-type="bibr" rid="article-18221.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18221.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Benztropine antagonizes acetylcholine and histamine receptors. Benztropine exerts its action in the CNS and smooth muscles by competing with acetylcholine at muscarinic receptors. Consequently, it reduces central cholinergic effects by blocking muscarinic receptors, which appears to alleviate the symptoms of Parkinson disease.<xref ref-type="bibr" rid="article-18221.r9">[9]</xref>&#x000a0;</p>
        <p>In vivo<italic toggle="yes">,</italic>&#x000a0;anticholinergic activity is&#x000a0;about half as potent as atropine.&#x000a0;Moreover, benztropine&#x000a0;may prolong the action of dopamine by inhibiting its reuptake and storage. Data from animal studies suggest that the antihistamine effect of benztropine&#x000a0;is similar to pyrilamine maleate.<xref ref-type="bibr" rid="article-18221.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The oral bioavailability of benztropine mesylate is low because of its limited gastric absorption and hepatic first-pass metabolism.</p>
        <p><bold>Distribution:</bold> Benztropine demonstrates high permeability across the blood-brain barrier, exerting a central anticholinergic effect.<xref ref-type="bibr" rid="article-18221.r11">[11]</xref></p>
        <p><bold>Metabolism:</bold> Benztropine has hepatic metabolism. In preclinical studies, administering benztropine (10 mg/kg body weight) to rats identified various metabolites in urine and bile. These metabolites include benztropine <italic toggle="yes">N</italic>-oxide, <italic toggle="yes">N</italic>-desmethylbenztropine, <italic toggle="yes">N</italic>-desmethyl-4'-hydroxybenztropine, 4'-hydroxybenztropine <italic toggle="yes">N</italic>-oxide, and methoxy-4'-hydroxybenztropine, along with the unchanged benztropine.<xref ref-type="bibr" rid="article-18221.r12">[12]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Metabolites of benztropine are&#x000a0;excreted in&#x000a0;urine and bile.<xref ref-type="bibr" rid="article-18221.r12">[12]</xref></p>
      </sec>
      <sec id="article-18221.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms, Strengths, and Adult Dosage</bold>
</p>
        <p>Benztropine is administered through oral, intravenous (IV), and intramuscular (IM) routes. Each route has a&#x000a0;particular advantage according to its specific indication.<xref ref-type="bibr" rid="article-18221.r13">[13]</xref></p>
        <p><bold>Oral Route:&#x000a0;</bold>Benztropine mesylate&#x000a0;is available in 0.5 mg, 1 mg, and 2 mg strengths for oral administration. The drug can be administered orally with no specific regard for meals.&#x000a0;The oral route is preferable to address initial and acute symptoms of drug-induced Parkinsonism.&#x000a0;Benztropine therapy may start with the lowest initial dose of 0.5 mg and may increase up to 6 mg for 5 to 6 days.&#x000a0;Benztropine has cumulative action, so the dose should gradually be increased by 0.5 mg until&#x000a0;optimal results are obtained without excessive adverse reactions.</p>
        <p><bold>IM route:&#x000a0;</bold>Benztropine mesylate&#x000a0;is available as a 1 mg/mL injection for IM&#x000a0;administration.&#x000a0;No significant clinical difference exists in the action of benztropine between&#x000a0;IM or&#x000a0;IV administration.&#x000a0;IM administration of benztropine typically leads to complete resolution of acute dystonia within 20 to 30 minutes, and a repeat dose can be considered after 30 minutes if full recovery is not achieved.<xref ref-type="bibr" rid="article-18221.r14">[14]</xref></p>
        <p><bold>IV route:&#x000a0;</bold>Benztropine mesylate&#x000a0;is available as a 1 mg/mL injection for IV administration. The IV route should be reserved for drug-induced extrapyramidal symptoms or whenever oral and IM administration are unsuitable.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The manufacturer label does not have information on benztropine&#x000a0;in patients with hepatic impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The manufacturer label does not have information on benztropine in patients with renal impairment.</p>
        <p><bold>Breastfeeding&#x000a0;considerations:&#x000a0;</bold>According to current&#x000a0;literature, the exact effects of benztropine on human breastfeeding are unknown. Furthermore, atropine, which shares structural similarities with benztropine, demonstrates little to no impact on human breastfeeding. However, some studies on antimuscarinic drugs, in general, have shown adverse effects on animal breastfeeding by reducing serum prolactin concentration in experimental animals. As a precautionary measure, it is advisable to contraindicate benztropine during breastfeeding.<xref ref-type="bibr" rid="article-18221.r15">[15]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The effect of benztropine during pregnancy and labor is still unknown. Several cases in the literature&#x000a0;discuss the impacts of benztropine administration during pregnancy. According to the literature, it is neither indicated nor contraindicated to use benztropine during pregnancy, as more clinical data and research are needed to detect the exact influence of benztropine.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Usually, pediatric patients are relatively more sensitive to anticholinergic agents. Therefore, benztropine is contraindicated in children younger than 3, infants, and neonates.</p>
        <p><bold>Older patients:</bold>&#x000a0;Older&#x000a0;patients are generally more sensitive to anticholinergic agents and respond relatively intensely to benztropine.&#x000a0;The dose should be started at&#x000a0;its lower end according to therapeutic needs. Additionally, oral benztropine is a&#x000a0;potentially inappropriate medication in treating geriatric patients that have Parkinson disease according to the American Geriatrics Society Beers criteria. Thus, clinicians should avoid the usage of benztropine as a preventative agent for extrapyramidal disorders in geriatric patients. In general, the geriatric population should avoid potent anticholinergic agents such as benztropine because of the higher incidence of&#x000a0;adverse effects among this group of patients. Common&#x000a0;adverse effects of benztropine in geriatrics are delirium, confusion, drug-induced dementia, benign prostatic hyperplasia in males, and urinary tract problems.<xref ref-type="bibr" rid="article-18221.r16">[16]</xref><xref ref-type="bibr" rid="article-18221.r17">[17]</xref></p>
      </sec>
      <sec id="article-18221.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Effects</bold>
</p>
        <p>The adverse effects of benztropine range in severity from mild to moderate to severe.<xref ref-type="bibr" rid="article-18221.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Mild adverse effects of benztropine may include fever, rash, general weakness, lethargy, insomnia, nausea, vomiting, headache, drowsiness, paraesthesia, xerostomia, and mydriasis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Moderate adverse effects associated with benztropine may manifest as myasthenia, heatstroke, heat intolerance, or hyperthermia, visual hallucinations, delirium, confusion, toxic psychosis, depression, worsening of preexisting psychotic symptoms, blurred vision, cycloplegia, memory impairment, dry mouth, parotitis, dysuria, urinary tract infections, sinus tachycardia, constipation, and numbness of fingers.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe adverse effects associated with benztropine may include toxic megacolon, ocular hypertension, paralytic&#x000a0;ileus&#x000a0;<xref ref-type="bibr" rid="article-18221.r19">[19]</xref>, and withdrawal of benztropine, leading to acute-onset dyskinesia.<xref ref-type="bibr" rid="article-18221.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The simultaneous administration of glucagon and anticholinergics, such as benztropine, is discouraged as it can lead to an escalation of gastrointestinal adverse reactions. This is attributed to the additive impact on inhibiting gastrointestinal motility.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent administration of benztropine with antipsychotic medications, including high-potency first-generation antipsychotics, clozapine, or quetiapine,&#x000a0;increases the risk of&#x000a0;gastrointestinal hypomotility.<xref ref-type="bibr" rid="article-18221.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Paralytic ileus, hyperthermia, and heat stroke can occur if benztropine is&#x000a0;combined&#x000a0;with phenothiazines (first-generation typical antipsychotic medications), tricyclic antidepressants, and other anticholinergics. Use with caution.<xref ref-type="bibr" rid="article-18221.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18221.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Boxed Warnings</bold>
</p>
        <p>Benztropine is contraindicated if the patient has a history of hypersensitivity to benztropine mesylate or any component of the drug formulation and children aged under 3.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Urinary retention, bladder obstruction, and prostatic hypertrophy:&#x000a0;</bold>Benztropine&#x000a0;should be used cautiously for bladder obstruction and benign prostatic hypertrophy because it&#x000a0;exerts anticholinergic effects. Also, benztropine may cause dysuria that can&#x000a0;aggravate urinary tract problems, especially urine retention.<xref ref-type="bibr" rid="article-18221.r23">[23]</xref></p>
        <p><bold>Angle-closure glaucoma:&#x000a0;</bold>Commonly, most anticholinergic drugs are avoided in closed-angle glaucoma. Benztropine is contraindicated in patients diagnosed with closed-angle glaucoma as it can cause mydriasis and cycloplegia. It can also lead to a significant increase in intraocular pressure indirectly.<xref ref-type="bibr" rid="article-18221.r24">[24]</xref></p>
        <p><bold>Tachycardia:&#x000a0;</bold>Benztropine use requires extreme caution in cardiac patients, especially those with tachycardia, as it can worsen tachycardia due to its anticholinergic action at the sinoatrial (SA) node.<xref ref-type="bibr" rid="article-18221.r25">[25]</xref></p>
        <p><bold>Tardive dyskinesia:&#x000a0;</bold>Long-term use of phenothiazines may cause the development of tardive dyskinesia. Although benztropine can be used to alleviate extrapyramidal symptoms, it is contraindicated for patients with tardive dyskinesia since benztropine and other anti-parkinsonian drugs can aggravate the symptoms of tardive dyskinesia instead of reducing them.<xref ref-type="bibr" rid="article-18221.r26">[26]</xref></p>
        <p><bold>Behavioral and psychological changes:&#x000a0;</bold>Benztropine may impair mental and physical abilities. It can also cause vision impairment, including blurring effects that can be highly risky when performing potentially hazardous tasks such as operating machinery or driving. Using benztropine for treating extrapyramidal disorders in psychotic patients may exaggerate the psychotic symptoms and behavioral changes. Thus, it should be contraindicated for such cases since anti-parkinsonian drugs, including benztropine, can lead to toxic psychosis. Besides, benztropine can cause visual hallucinations and mental confusion at a relatively higher dosage. Also,&#x000a0;the drug&#x000a0;can intensify the symptoms of dementia, so it should be contraindicated in dementia patients.<xref ref-type="bibr" rid="article-18221.r27">[27]</xref></p>
        <p><bold>Myasthenia gravis and autonomic neuropathy:&#x000a0;</bold>The anticholinergic effects of benztropine cause muscle weakness as it competes with acetylcholine at the neuromuscular junction. Thus, like other anticholinergic drugs, benztropine should be avoided in patients diagnosed with myasthenia gravis and autonomic neuropathy. If the patient starts to feel stiffness in the neck, followed by sudden relaxation, it indicates the need to adjust the benztropine dose.<xref ref-type="bibr" rid="article-18221.r28">[28]</xref></p>
        <p><bold>Alcoholism and hyperthermia:&#x000a0;</bold>The similar structure and function between benztropine and atropine as anticholinergic agents can cause anhydrosis. The administration&#x000a0;of benztropine in individual patients should be slow and under extreme caution. For instance, giving benztropine to patients with hyperthermia, alcoholism, who perform manual labor in a hot environment, and patients taking other atropine-like medications require extreme caution. Common signs of anhydrosis induced by benztropine are a disturbance in sweating and the development of hyperthermia.<xref ref-type="bibr" rid="article-18221.r29">[29]</xref></p>
        <p><bold>Contact lenses:&#x000a0;</bold>Generally, anticholinergic drugs, including benztropine, usually cause eye dryness. Thus, patients who typically wear contact lenses may feel discomfort. Consequently,&#x000a0;clinicians should advise patients to apply lubricant eye drops (artificial tears) before using contact lenses to relieve dryness. Patients should avoid contact lens use during benztropine treatment if the eye dryness is severe.</p>
      </sec>
      <sec id="article-18221.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring the response to benztropine treatment and any unwanted anticholinergic effects is essential. For instance, patients with mental disorders can have a wide variety of reactions to benztropine treatment. Thus, they should be kept under close monitoring and observation, especially at the beginning of the treatment or when a dose increment is required in their cases to prevent any&#x000a0;aggravation of&#x000a0;neurological&#x000a0;symptoms.<xref ref-type="bibr" rid="article-18221.r27">[27]</xref></p>
        <p>Geriatric patients are more sensitive and have an intense response to anticholinergic medicines. Thus, the healthcare team should give extra attention to the dose and its effects on the patient's other pre-existing disorders. During benztropine use in geriatric patients, the dose should be started at the lower end because of higher sensitivity to the drug's adverse effects, like confusion and sedation.<xref ref-type="bibr" rid="article-18221.r16">[16]</xref>&#x000a0;Sufficient clinical monitoring is essential for benztropine administration in a relatively warm environment, as it can cause anhydrosis in specific groups of patients. In other words, the administration&#x000a0;of benztropine should be careful in alcoholic patients and patients conducting manual labor in hot and humid weather. Therefore, meticulous supervision and monitoring are required.<xref ref-type="bibr" rid="article-18221.r30">[30]</xref></p>
      </sec>
      <sec id="article-18221.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Benztropine has been&#x000a0;in use for over 50 years, and no reported incidents of liver injury exist due to the drug. The absence of liver injury is typical of anticholinergic agents and may also relate to the low therapeutic dose. However, benztropine overdose can cause an anticholinergic toxidrome, which, in its role, may require supportive care. The risk assessment for benztropine overdose can take place as soon as 6 hours after ingestion, and toxicity effects may vary between 12 hours and&#x000a0;5 days.<xref ref-type="bibr" rid="article-18221.r30">[30]</xref>&#x000a0;The most crucial step of proper detection of benztropine overdose involves conducting thorough investigations. It is recommended to obtain a 12-lead electrocardiogram (ECG).&#x000a0;Monitoring the&#x000a0;drug concentrations and blood glucose concentrations can become valuable for toxicity investigations if the toxicant is unknown. Patients who do not exhibit specific toxicity symptoms may need additional investigations, such as a lumbar puncture or brain CT scan.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Physostigmine is the antidote for benztropine toxicity in the&#x000a0;event delirium is not controlled through benzodiazepines. It can be used for toxicity diagnosis if the patient regains a normal state after administration. However, caution should be practiced in determining its proper dose and route of administration since it can cause a cholinergic crisis that endangers the patient's life.<xref ref-type="bibr" rid="article-18221.r31">[31]</xref>&#x000a0;Decontaminating benztropine toxicity in cooperative and alert patients occurs by administering 50 g of activated charcoal during the first 2 hours of benztropine ingestion. Proper supportive care includes controlling delirium through IV administration of benzodiazepines such as diazepam. Also, catheter and bladder scans can help in case of urinary retention.<xref ref-type="bibr" rid="article-18221.r32">[32]</xref></p>
      </sec>
      <sec id="article-18221.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The effective management of benztropine dosage and administration methods necessitates collaboration among interprofessional healthcare teams. The coordinated efforts of healthcare team members, including clinicians, neurologists, pharmacists, and nurses, can markedly enhance patient outcomes and contribute to successfully managing symptoms requiring benztropine therapy.&#x000a0;</p>
        <p>Prescribers should start benztropine at a lower dosage and taper on gradually, especially in the geriatric population and patients with mental or behavioral issues. Neurologists should be consulted for advanced cases. Nurses should monitor patients for therapeutic success and any adverse events. When benztropine overdose is suspected, ICU nursing staff should monitor patients until the resolution of toxicity symptoms. The pharmacist can verify the appropriate dosing for the patient and review the patient's medication profile to find potential drug interactions. The ultimate objective is empowering healthcare professionals to deliver precise, patient-centered care, significantly improving management outcomes.</p>
      </sec>
      <sec id="article-18221.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18221&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18221">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18221/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18221">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18221.s11">
        <title>References</title>
        <ref id="article-18221.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Benztropine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Koller</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lannon</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Busenbark</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Swanson-Hyland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>1077</fpage>
            <page-range>1077-81</page-range>
            <pub-id pub-id-type="pmid">9109903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>PAULSON</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>BUFFALOE</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>SOME REMARKS ON THE TREATMENT OF POST-ENCEPHALITIC OCULOGYRIC CRISES WITH BENZTROPINE METHANESULFONATE.</article-title>
            <source>Int J Neuropsychiatry</source>
            <year>1965</year>
            <season>May-Jun</season>
            <volume>1</volume>
            <fpage>214</fpage>
            <page-range>214-5</page-range>
            <pub-id pub-id-type="pmid">14309084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ananth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sangani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Noonan</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Amantadine in drug-induced extrapyramidal signs: a comparative study.</article-title>
            <source>Int J Clin Pharmacol Biopharm</source>
            <year>1975</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <page-range>323-6</page-range>
            <pub-id pub-id-type="pmid">239908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sivaramakrishnan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.</article-title>
            <source>J Clin Neurosci</source>
            <year>2018</year>
            <month>May</month>
            <volume>51</volume>
            <fpage>12</fpage>
            <page-range>12-17</page-range>
            <pub-id pub-id-type="pmid">29475576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paine</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Snider</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>When saliva becomes a problem: the challenges and palliative care for patients with sialorrhea.</article-title>
            <source>Ann Palliat Med</source>
            <year>2020</year>
            <month>May</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>1333</fpage>
            <page-range>1333-1339</page-range>
            <pub-id pub-id-type="pmid">32279509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>Benztropine for the treatment of intractable hiccups: New indication for an old drug?</article-title>
            <source>CJEM</source>
            <year>2002</year>
            <month>May</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-6</page-range>
            <pub-id pub-id-type="pmid">17609007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Procyshyn</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Samii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carleton</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>349</fpage>
            <page-range>349-356</page-range>
            <pub-id pub-id-type="pmid">29901567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chouinard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Annable</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ross-Chouinard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kropsky</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Ethopropazine and benztropine in neuroleptic-induced parkinsonism.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1979</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <page-range>147-52</page-range>
            <pub-id pub-id-type="pmid">33969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raje</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eddington</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>307</volume>
            <issue>2</issue>
            <fpage>801</fpage>
            <page-range>801-8</page-range>
            <pub-id pub-id-type="pmid">12966155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Midha</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Phase I and II metabolites of benztropine in rat urine and bile.</article-title>
            <source>Xenobiotica</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>857</fpage>
            <page-range>857-72</page-range>
            <pub-id pub-id-type="pmid">8779226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brocks</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective.</article-title>
            <source>J Pharm Pharm Sci</source>
            <year>1999</year>
            <season>May-Aug</season>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">10952768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathews</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gratz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adetunji</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basil</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic-induced movement disorders: evaluation and treatment.</article-title>
            <source>Psychiatry (Edgmont)</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>36</fpage>
            <page-range>36-41</page-range>
            <pub-id pub-id-type="pmid">21179628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Benztropine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>12</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30000721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergics in dementia and other confounding problems.</article-title>
            <source>Am J Geriatr Psychiatry</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>384; author reply 384</fpage>
            <page-range>384; author reply 384-5</page-range>
            <pub-id pub-id-type="pmid">16582052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siris</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Rifkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reardon</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>November</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate.</article-title>
            <source>Am J Psychiatry</source>
            <year>1983</year>
            <month>Aug</month>
            <volume>140</volume>
            <issue>8</issue>
            <fpage>1069</fpage>
            <page-range>1069-71</page-range>
            <pub-id pub-id-type="pmid">6346910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denka</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Paralytic ileus requiring hospitalization secondary to high-dose antipsychotic polypharmacy and benztropine.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2011</year>
            <season>Mar-Apr</season>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>200.e5</fpage>
            <page-range>200.e5-7</page-range>
            <pub-id pub-id-type="pmid">21596217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thalner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report.</article-title>
            <source>WMJ</source>
            <year>2023</year>
            <month>May</month>
            <volume>122</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-145</page-range>
            <pub-id pub-id-type="pmid">37141483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study.</article-title>
            <source>Schizophr Res</source>
            <year>2018</year>
            <month>May</month>
            <volume>195</volume>
            <fpage>237</fpage>
            <page-range>237-244</page-range>
            <pub-id pub-id-type="pmid">29107449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudolph</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Salow</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Angelini</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>McGlinchey</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>The anticholinergic risk scale and anticholinergic adverse effects in older persons.</article-title>
            <source>Arch Intern Med</source>
            <year>2008</year>
            <month>Mar</month>
            <day>10</day>
            <volume>168</volume>
            <issue>5</issue>
            <fpage>508</fpage>
            <page-range>508-13</page-range>
            <pub-id pub-id-type="pmid">18332297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Person</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Izekor</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Ahmadian</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>An Unlikely Case of Benztropine Misuse in an Elderly Schizophrenic.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Feb</month>
            <day>18</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>e13434</fpage>
            <pub-id pub-id-type="pmid">33758719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Blouin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Outpatient psychiatric medications and glaucoma.</article-title>
            <source>Psychosomatics</source>
            <year>1976</year>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-5</page-range>
            <pub-id pub-id-type="pmid">7801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raehl</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>LeRoy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced torsade de pointes.</article-title>
            <source>Clin Pharm</source>
            <year>1985</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>675</fpage>
            <page-range>675-90</page-range>
            <pub-id pub-id-type="pmid">2416504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Soares-Weiser</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic medication for antipsychotic-induced tardive dyskinesia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Jan</month>
            <day>17</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD000204</fpage>
            <pub-id pub-id-type="pmid">29341071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Clinebell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chengappa</surname>
                <given-names>KNR</given-names>
              </name>
            </person-group>
            <article-title>Reducing Anticholinergic Medication Burden in Patients With Psychotic or Bipolar Disorders.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2017</year>
            <season>Nov/Dec</season>
            <volume>78</volume>
            <issue>9</issue>
            <fpage>e1270</fpage>
            <page-range>e1270-e1275</page-range>
            <pub-id pub-id-type="pmid">29178683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howrie</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Krenzelok</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Benztropine-induced acute dystonic reaction.</article-title>
            <source>Ann Emerg Med</source>
            <year>1986</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>594</fpage>
            <page-range>594-6</page-range>
            <pub-id pub-id-type="pmid">3963542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stadnyk</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Glezos</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced heat stroke.</article-title>
            <source>Can Med Assoc J</source>
            <year>1983</year>
            <month>Apr</month>
            <day>15</day>
            <volume>128</volume>
            <issue>8</issue>
            <fpage>957</fpage>
            <page-range>957-9</page-range>
            <pub-id pub-id-type="pmid">6831343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McIntyre</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Mallett</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Morhaime</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute benztropine intoxication and fatality.</article-title>
            <source>J Forensic Sci</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>1675</fpage>
            <page-range>1675-8</page-range>
            <pub-id pub-id-type="pmid">24697166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornton</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Farnaes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Minns</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prolonged Antimuscarinic Delirium in a Child Due to Benztropine Exposure Treated With Multiple Doses of Physostigmine.</article-title>
            <source>Pediatr Emerg Care</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-5</page-range>
            <pub-id pub-id-type="pmid">26383155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18221.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kotsos</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fatal benztropine toxicity.</article-title>
            <source>Med Sci Law</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-8</page-range>
            <pub-id pub-id-type="pmid">11368397</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
